• MetaVia flagged new Phase 1 higher-dose cohort data for obesity drug candidate DA-1726, a dual GLP-1/glucagon agonist, in a late-breaking poster accepted for EASL Congress 2026.
• Results have not yet been presented; poster is scheduled for May 27, 2026 in Barcelona.
• Readout is set to focus on safety, tolerability, drug exposure, pharmacodynamic activity, with an exploratory noninvasive liver assessment, positioning the program for dose optimization and potential differentiation in obesity.
• Company is running a 16-week Phase 1 Part 3 titration study to test higher dose levels and improve tolerability, with additional data expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605110831PR_NEWS_USPR_____NY55071) on May 11, 2026, and is solely responsible for the information contained therein.